PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026Journal of Medical Economics0 citationsOpen Access

Cost-effectiveness of female-only and gender-neutral HPV vaccination strategies in Japan

View Full Paper
MKMinjin KimESEunha Shim

Key Points

  • Evaluate the cost-effectiveness of female-only vs. gender-neutral HPV vaccination in Japan.
  • Comparison of 4vHPV and 9vHPV strategies
  • Analysis based on Japan's economic standards
  • Assessment of health benefits
  • Both female-only 4vHPV and 9vHPV strategies are cost-effective
  • Gender-neutral vaccination with 9vHPV offers greater health benefits and cost-effectiveness

Abstract

Both female-only 4vHPV and 9vHPV strategies are cost-effective under Japan's economic standards. Furthermore, GNV with 9vHPV provides greater health benefits and cost-effectiveness.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/696719b10a9733890c4ee1bfhttps://doi.org/10.1080/13696998.2025.2609508
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cost-effectiveness of extending human papillomavirus (HPV) vaccination programmes to boys in Japan2026
  2. 2Health impact and cost-effectiveness analysis of gender-neutral versus female-only 9-valent human papillomavirus vaccination in Taiwan2025
  3. 3Cost-effectiveness modeling for gender-neutral human papillomavirus vaccines: A systematic literature review2025
  4. 4Cost-effectiveness and epidemiological impact of gender-neutral vaccination against human papillomavirus in economically developed metropolises of Beijing, Shanghai, and Guangzhou, China.2025
  5. 5The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based study2025